Pliant Therapeutics Shares it 52-Week Low

Pliant Therapeutics stock tumbles amid IPF trial cancellation
The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.
Pliant Therapeutics Shares it 52-Week Low After Phase2b Trial Discontinued
Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week low of $1.53 earlier in the session, and is now down 90% n the past 12 months.
Pliant Therapeutics shares rise on better-than-expected Q4 earnings
SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The cli
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel,
Pliant Therapeutucs Shares Halted After Bexotegrast Phase 2b Trial Discontinued
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis.
Pliant Therapeutics price target lowered to $1.50 from $4 at Citi
Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...
With Congress Pliant, an Emboldened Trump Pushes His Business Interests
Norms recognized for decades in Washington by both parties no longer appear to apply to the Trump White House, former ...
Hosted on MSN20h
NAB Show: Pliant To Intro Dual Listen To CrewCom CB2
Pliant Technologies’ CrewCom CB2 Professional Wireless Intercom system is a full-duplex, install-friendly and feature-packed solution for small to mid-level applications requiring a reliable, great ...
Pliant Therapeutics (PLRX) Projected to Post Earnings on Tuesday
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...